Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.

doi:10.1111/j.1440-1843.2006.00940.x

Back to search

Article

Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.

Respirology (Carlton, Vic.) - 1 Nov 2006

Kato Tefurumi, Nishio Kazuto

Abstract excerpt

Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth factor receptor (EGFR) tyrosine kinase activity. Developmental studies of either drug have failed to show synergistic effects when combined with cytotoxic drugs as the first line treatment in patients with advan...

Topics

Antineoplastic Agents
Asian People
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
ErbB Receptors
Erlotinib Hydrochloride
Female
Gefitinib
Humans
Lung Neoplasms
Male
Mutation
Protein Kinase Inhibitors
Protein-Tyrosine Kinases
Quinazolines

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.